Pune-headquartered Emcure Pharmaceuticals has successfully completed the first year of its ambitious five-year strategic plan, achieving significant financial performance largely propelled by its international markets and a focus on margin expansion. The drugmaker reported an impressive revenue exceeding US$1 billion for the fiscal year 2026.
International Business Drives Growth
Emcure's international business segment demonstrated robust momentum, growing by 22.2% year-on-year to ₹5,177 crore in FY26. This growth significantly outpaced its domestic segment, which saw a 10% increase to ₹4,027 crore. The expansion in overseas markets was attributed to both the growth of its existing base business and the successful launch of new products across key regions, including Europe and Canada.
Satish Mehta, CEO and Managing Director of Emcure, highlighted the company's strong performance, stating, “In FY26, the first year of our five-year strategic plan, Emcure delivered strong financial performance with over US$1 billion in revenue and 16.6% growth.” He further emphasized the company's commitment to “sustainable, above-industry growth and consistent margin expansion.”
Strategic Pipeline and Acquisitions
A key driver for future growth remains Emcure's strengthening pipeline in complex injectables and biosimilars. The company is strategically expanding its presence in highly regulated markets such as Europe and Canada, reinforcing its global footprint.
During the fiscal year, Emcure also engaged in several strategic deals to bolster its portfolio. This included completing a minority stake buyout in Zuventus Healthcare and executing bolt-on acquisitions in the UK and Canada. Additionally, the company pursued in-licensing arrangements to further enhance its product offerings and market reach.
Financial Highlights for FY26
For the full fiscal year 2026, Emcure Pharmaceuticals reported revenue from operations totaling ₹9,204 crore, marking a 16.6% year-on-year increase and surpassing its stated guidance. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) rose by 21.8% to ₹1,789 crore, leading to an improved margin of 19.4%. Profit After Tax (PAT) stood at ₹941 crore, up 33.1%, with adjusted PAT increasing by 40.9% to ₹1,008 crore.
In the fourth quarter of FY26, the company's revenue grew by 16.7% year-on-year to ₹2,470 crore. EBITDA for the quarter increased by 24.5% to ₹485 crore, and adjusted PAT saw a 36% rise to ₹279 crore.